Samjot Singh Dhillon1, Adrienne Groman2, Alison Meagher3, Todd Demmy4, Graham W Warren5, Sai Yendamuri4. 1. Department of Medicine-Thoracic Oncology/Pulmonary Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA. 2. Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA. 3. Department of Pharmacy, Roswell Park Cancer Institute, Buffalo, NY, USA. 4. Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, NY, USA. 5. Department of Radiation Oncology and Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA.
Abstract
BACKGROUND: Published data suggest that diabetes influences survival of patients with lung cancer. The anti-cancer effect of metformin confounds this association. We sought to study the association of diabetes and metformin with survival in patients undergoing resection of stage I non-small cell lung cancer (NSCLC). METHODS: Pathologic stage I NSCLC patients undergoing anatomic resection from 2002 to 2011 were studied. A diagnosis of diabetes and diabetic medication use were identified through records. Univariate and multivariate analyses examined the association of diabetes and metformin usage with overall survival (OS). RESULTS: 409 eligible patients were included in the analysis - excluding patients with neoadjuvant therapy, more than one lung cancer, or resection less than lobectomy. 71 (17.4%) patients were diabetics and 41 (10.0%) used metformin. With a median follow up of 44 months, univariate analysis demonstrates that diabetes had no effect on OS (P=0.75); however, metformin use was associated with improved OS (median survival not reached vs. 60 months; P=0.02). Metformin use remained an important predictor of good survival in multivariate analysis (HR=3.08; P<0.01) after adjusting for age, gender, pathologic stage, histology and smoking status. CONCLUSION: Metformin use rather than diabetes is associated with improved long-term survival in Stage I NSCLC patients.
BACKGROUND: Published data suggest that diabetes influences survival of patients with lung cancer. The anti-cancer effect of metformin confounds this association. We sought to study the association of diabetes and metformin with survival in patients undergoing resection of stage I non-small cell lung cancer (NSCLC). METHODS: Pathologic stage I NSCLCpatients undergoing anatomic resection from 2002 to 2011 were studied. A diagnosis of diabetes and diabetic medication use were identified through records. Univariate and multivariate analyses examined the association of diabetes and metformin usage with overall survival (OS). RESULTS: 409 eligible patients were included in the analysis - excluding patients with neoadjuvant therapy, more than one lung cancer, or resection less than lobectomy. 71 (17.4%) patients were diabetics and 41 (10.0%) used metformin. With a median follow up of 44 months, univariate analysis demonstrates that diabetes had no effect on OS (P=0.75); however, metformin use was associated with improved OS (median survival not reached vs. 60 months; P=0.02). Metformin use remained an important predictor of good survival in multivariate analysis (HR=3.08; P<0.01) after adjusting for age, gender, pathologic stage, histology and smoking status. CONCLUSION:Metformin use rather than diabetes is associated with improved long-term survival in Stage I NSCLCpatients.
Authors: Sandra L Starnes; Peterson Pathrose; Jiang Wang; Paul Succop; John C Morris; James Bridges; Elena Y Kupert; Marshall Anderson Journal: Ann Thorac Surg Date: 2012-03-20 Impact factor: 4.330
Authors: J Varlotto; L N Medford-Davis; A Recht; J Flickinger; E Schaefer; J Shelkey; M Lazar; D Campbell; M Nikolov; M M Decamp Journal: Lung Cancer Date: 2011-08-23 Impact factor: 5.705
Authors: Edward Giovannucci; David M Harlan; Michael C Archer; Richard M Bergenstal; Susan M Gapstur; Laurel A Habel; Michael Pollak; Judith G Regensteiner; Douglas Yee Journal: CA Cancer J Clin Date: 2010-06-16 Impact factor: 508.702
Authors: Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Alexander Thompson; Emanuele Di Angelantonio; Pei Gao; Nadeem Sarwar; Sreenivasa Rao Kondapally Seshasai; Stephen Kaptoge; Peter H Whincup; Kenneth J Mukamal; Richard F Gillum; Ingar Holme; Inger Njølstad; Astrid Fletcher; Peter Nilsson; Sarah Lewington; Rory Collins; Vilmundur Gudnason; Simon G Thompson; Naveed Sattar; Elizabeth Selvin; Frank B Hu; John Danesh Journal: N Engl J Med Date: 2011-03-03 Impact factor: 91.245
Authors: Craig J Currie; Chris D Poole; Sara Jenkins-Jones; Edwin A M Gale; Jeffrey A Johnson; Christopher Ll Morgan Journal: Diabetes Care Date: 2012-01-20 Impact factor: 19.112
Authors: Sai Yendamuri; Joseph Barbi; Sarabjot Pabla; Cara Petrucci; Achamaporn Punnanitinont; Mary Nesline; Sean T Glenn; Paul Depietro; Antonios Papanicalou-Sengos; Carl Morrison; Grace K Dy; Peter L Elkin Journal: J Thorac Oncol Date: 2019-08-06 Impact factor: 15.609
Authors: Peter L Elkin; Sarah Mullin; Sheldon Tetewsky; Skyler D Resendez; Wilmon McCray; Joseph Barbi; Sai Yendamuri Journal: J Thorac Cardiovasc Surg Date: 2022-03-10 Impact factor: 6.439
Authors: Suzan Brancher; Nathalie C Støer; Elisabete Weiderpass; Ronald A M Damhuis; Tom B Johannesen; Edoardo Botteri; Trond-Eirik Strand Journal: Br J Cancer Date: 2020-12-02 Impact factor: 7.640